Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Trial Identifier: D831AC00002
Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd.
Collaborator:
Suzhou Gracell Biotechnologies, Co., Ltd.
Start Date: October 2025
Primary Completion Date: November 2028
Study Completion Date: November 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, CN-100730
CN Beijing, CN, 100034
CN Beijing, CN, 100070
CN Changchun, CN, 130021
CN Guangzhou, CN, 510100
CN Hangzhou, CN, 310003
CN Suzhou, CN, 215006
CN Wenzhou, CN, 325000
CN Wuhan, CN, 430022